UCB Patents

Matching "UCB" by Owner.



Contents

Alerts	3
"UCB"	3
Terms and Conditions	10
General	10
Disclaimer of warranty and limitation of liability	10
Copyright	10
Arbitration	10

Alerts

"UCB"

185 results matching "UCB" by Owner.

Number	Title	Owner
2002302447	USE OF CERTAIN SUBSTITUTED PYRROLIDONES SUCH AS PIRACETAM IN THE TREATMENT OF VIRAL AND OTHER DISEASES	UCB, S.A.
<u>2002302553</u>	PHOTO-INITIATOR COMPOSITIONS	UCB, S.A.
2002308258	LABELS	UCB, S.A.
2002314086	2-OXO-PIPERIDINYLAND 2-OXO-AZEPANYL ALKANOIC ACID DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND OTHER NEUROLOGICAL DISORDERS	UCB, S.A.
2002314089	THERMOSETTING ACRYL POWDER COATING	UCB, S.A.
2002315299	THERMOSETTING POWDER COMPOSITIONS FOR COATINGS	UCB, S.A.
<u>2002312988</u>	METHOD FOR THE PRODUCTION OF CELLULOSIC FLAT FILMS	UCB S.A.
<u>2002317851</u>	THERMOSETTING POWDER COMPOSITIONS FOR COATINGS	MAETENS, Daniel ; UCB, S.A. ; MOENS, Luc ; KNOOPS, Nele
2002321256	RADIATION CURABLE POWDER COATING COMPOSITIONS	UCB, S.A.
2002325355	Process for the preparation of 2-(2-(4-BIS(4- fluorophenyl)-piperazin-1YL)ethoxy)acetic acid derivatives or corresponding salt forms yhereof and immediates therefor	UCB
<u>2002246601</u>	POWDER COATING COMPOSITIONS CONTAINING REACTIVE NANOPARTICLES	UCB, S.A.
2002325823	PACKAGING FILM	UCB, S.A. ; DUTTON, Neill
2002325893	POLYMERIC COMPOSITIONS	UCB, S.A.
<u>2002329233</u>	Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues	UCB
2002240842	POWDERED THERMOSETTING COMPOSITION FOR COATINGS	UCB, S.A.
2002334135	Antibodies against KDR, their production and uses	UCB Pharma S.A.
2002333267	POLYMERIC COMPOSITIONS	UCB, S.A.
2002333333	PREPARATION OF A COMPOUND CONTAINING CYCLIC AND LINEAR CARBONATE GROUPS	UCB, S.A.
<u>2002333469</u>	DEODORIZING AGENT FOR SULFUROR NITROGEN-CONTAINING INITIATORS	UCB, S.A.
2002333880	Pyrrolidinone derivatives	UCB, S.A.
2002250912	CATIONICALLY CURABLE COMPOSITIONS CONTAINING TRIARYLCYCLOPROPENYLIUM SALTS	UCB, S.A.
2002336105	LABELLED ARTICLES AND USES THEREOF	UCB, S.A.

Number	Title	Owner
<u>2002337067</u>	FORMING AN EMBOSSED COATED SUBSTRATE	UCB, S.A.
<u>2002337126</u>	Quinuclidine derivatives, processes for preparing them and their uses as M2 and/or M3 muscarinic receptor inhibitors	UCB, S.A.
2002337127	WATER PERMEABLE SHEET AND USES THEREOF	UCB, S.A.
2002337144	COATED FILM	UCB, S.A.
<u>2002338402</u>	IMPROVED RADIATION CURABLE COMPOSITION	UCB, S.A.
<u>2002340563</u>	STRETCHED AND VOIDED POLYMERIC FILM	UCB, S.A.
2002340971	Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders	UCB
2002344152	POLYMER COMPOSITIONS AND USES THEREOF	UCB, S.A.
2002245486	Treatment of tics, tremors and related disorders	UCB, S.A.
<u>2002345024</u>	Tablet comprising cetirizine and pseudoephedrine	UCB Farchim SA
<u>2002345833</u>	METHOD FOR THE PRODUCTION OF CELLULOSIC FLAT FILMS	UCB S.A.
2001252144	2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses	UCB
<u>2002238564</u>	PHOSPHORUS CONTAINING MATERIALS, THEIR PREPARATION AND USE	UCB, S.A.
<u>2002350901</u>	Expression control using variable intergenic sequences	UCB Pharma S.A.
<u>2002354540</u>	ENERGY CURABLE POLYMERIC INK COMPOSITIONS	UCB, S.A.
<u>2002354868</u>	RADIATION CURABLE POWDER COATING COMPOSITIONS	UCB, S.A.
<u>2002355174</u>	RADIATION CURABLE POLYMERIC INK COMPOSITIONS	UCB, S.A.
2002355455	COMPOSITE COMPOSITIONS	UCB, S.A.; VAN DEN BERGEN, Hugues
<u>2002356776</u>	ULTRASONIC METHOD FOR THE PRODUCTION OF INORGANIC/ORGANIC HYBRID NANOCOMPOSITE	UCB, S.A.
2003201161	Formulations	UCB Farchim S.A.
2002257687	SUBSTRATES, PREPARATION AND USE	UCB, S.A.
<u>2002358087</u>	RADIATION-CURABLE POLYURETHANE DISPERSION	UCB, S.A.
<u>2003202550</u>	PHARMACEUTICAL FORMULATIONS WITH MODIFIED RELEASE	UCB, S.A.
2002257793	BATTERY SEPARATORS	UCB, S.A.
<u>2002362529</u>	GENES ASSOCIATED WITH MAST CELL ACTIVATION	UCB, S.A.
<u>2003208867</u>	FILMS, PACKAGING AND METHODS FOR MAKING THEM	UCB, S.A.
2003212368	PRINTABLE FILM	UCB, S.A.
2003215587	METAL COATED FILM	UCB, S.A.
<u>2003227739</u>	RADIATION CURABLE COMPOSITIONS	UCB, S.A.
<u>2003229741</u>	THERAPEUTIC AGENT COMPRISING LAFUTIDINE	UCB, S.A.

Number	Title	Owner
2003223007	Antibodies specific for human CD22 and their therapeutic and digagnostic uses	UCB Pharma S.A.
2003222289	BATTERY SEPARATORS	UCB, S.A.
2003222747	PACKAGING METHODS AND PACKS MADE THEREBY	UCB, S.A.
2003222786	CHEMICAL COMPOUNDS WITH DUAL ACTIVITY, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS	UCB, S.A.
<u>2002366742</u>	RADIATION CURABLE COMPOSITIONS FOR PIGMENTED LIQUID INKS	UCB, S.A.
2003232472	2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors	UCB Pharma
<u>2003235722</u>	POLYMERIC COMPOSITIONS	UCB, S.A.
<u>2003237695</u>	AUTHENTICATION MEANS	UCB, S.A.
<u>2003238399</u>	Use of levocetirizine for the treatment of persistent allergic rhinitis	UCB Farchim S.A.
<u>2003239855</u>	WATER-DILUTABLE/DISPERSIBLE RADIATION CURABLE COMPOSITIONS	UCB, S.A.
<u>2003242538</u>	USE OF 2-OXO-1-PYRROLIDONE DERIVATIVES FOR THE PREPARATION OF A DRUG	UCB, S.A.
2003242760	COATING COMPOSITIONS	UCB, S.A.
<u>2003242761</u>	APPARATUS AND METHOD FOR SCORING A PACKAGING FILM	UCB, S.A.
<u>2003244476</u>	PROCESS USING A CYCLIC CARBONATE REACTANT	UCB, S.A.
<u>2003246640</u>	WATER-THINNABLE POLYMER PRECURSORS, THEIR PREPARATION AND USE	UCB, S.A.
<u>2003249881</u>	DIARYLMETHYLPIPERAZINES AS PROPHYLACTIC OR THERAPEUTIC AGENTS FOR VIRAL MYOCARDITIS	UCB, S.A.
<u>2003250088</u>	POLYMERIC FILM	UCB, S.A.
<u>2003250919</u>	ACRYLIC PRESSURE SENSITIVE ADHESIVES	UCB, S.A.
2003253087	Arylamine substututed bicyclic heteroaromatic compounds as P38 kinase inhibitors	UCB Pharma S.A.
<u>2003252990</u>	Bicyclic heteroaromatic compounds as kinase inhibitors	UCB Pharma S.A.
<u>2003254368</u>	COLOURED LABELS	UCB, S.A.
2003264069	METHOD FOR BONDING DVD LAYERS	UCB, S.A.
<u>2003264119</u>	REACTIVE AND GEL-FREE COMPOSITIONS FOR MAKING HYBRID COMPOSITES	UCB, S.A.
<u>2003270291</u>	4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS	UCB, S.A.
<u>2003271870</u>	Bicyclic heteroaromatic compounds as kinase inhibitors	UCB Pharma S.A.
2003271717	FLAME RETARDANT COMPOSITION	UCB, S.A.
<u>2003278972</u>	REMOVABLE, WATER-WHITENING RESISTANT PRESSURE SENSITIVE ADHESIVES	UCB, S.A.

Number	Title	Owner
<u>2003278976</u>	REMOVABLE, WATER-WHITENING RESISTANT PRESSURE SENSITIVE ADHESIVES	UCB, S.A.
2003279355	SEMI-GLOSS POWDER COATING COMPOSITIONS	UCB, S.A.
2003280965	Phenylalanine enamide derivatives	UCB Pharma S.A.
2003280967	Process for the preparation of phenylalanine enamide derivatives	UCB Pharma S.A.
2003282055	POWDER COATING COMPOSITIONS CONTAINING ANHYDRIDE ENDCAPED CRYSTALLINE POLYESTERS	UCB, S.A.
<u>2003285578</u>	Assay for identifying antibody producing cells	UCB Pharma S.A.
2003288041	TABLET COMPRISING EFLETIRIZINE AND PSEUDOEPHEDRINE	UCB, S.A.
<u>2003288098</u>	PROCESS FOR PRODUCING CARBAMOYLOXY (METH)ACRYLATES AND NEW CARBAMOYLOXY (METH)ACRYLATES	UCB, S.A.
<u>2003289920</u>	POLYMER COMPOSITIONS	UCB, S.A.
<u>2003298220</u>	ADHESIVES	UCB, S.A.
<u>2003298766</u>	Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases	UCB, S.A.
<u>2003301318</u>	E.coli host cells with modified PhoS/ psts periplasmic phosphate-binding proteins, and method of manufacturing recombinant fabs	UCB Pharma S.A.
2005200717	2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses	UCB Farchim S.A. (AG-Ltd)
2005200718	2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses	UCB Farchim S.A. (AG-Ltd)
2004204338	Hydrogenation catalysts	UCB, S.A.
2005203271	2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses	UCB
2005203275	2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses	UCB
2005203276	2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses	UCB Pharma
2004205494	Piperazine derivatives and their use as synthesis intermediates	UCB Farchim SA
<u>2004210776</u>	Antibody molecules having specificity for human IL-1beta	UCB Pharma S.A.
2004226288	Indolone-acetamide derivatives, processes for preparing them and their uses	UCB, S.A.
2004249498	Thienopyridone derivatives as kinase inhibitors	UCB Pharma S.A.
2004253870	Compositions and methods for increasing bone mineralization	UCB Manufacturing, Inc.
<u>2004262640</u>	Antibodies specific for sclerostin and methods for increasing bone mineralization	UCB Manufacturing, Inc.
2004270929	Methods for producing recombinant proteins	UCB Pharma S.A.
<u>2004274157</u>	Process for preparing 2-oxo-1-pyrrolidine derivatives	UCB Pharma
2004285339	A protein involved in ovarian cancer	UCB Pharma S.A.
2004289098	Use of an inhibitor of CSF-1 activity for the treatment of inflammatory bowel disease	UCB Pharma S.A.

Number	Title	Owner
2004292393	Method for the treatment of multiple sclerosis by inhibiting IL-17 activity	UCB Pharma S.A
<u>2004298341</u>	(S)-2-N-propylamino-5-hydroxytetralin as a D3- agonist	UCB Pharma GmbH
2004295083	Imidazole derivatives, processes for preparing them and their uses	UCB Pharma
<u>2004305291</u>	Branched polyethylene glycol for linking polymer residues to antibodies	UCB Pharma S.A.
2004308648	Use of rotigotine for the treatment or prevention of dopaminergic neurone loss	UCB Pharma GmbH
2005226911	Use of rotigotine for treating and preventing Parkinson's plus syndrome	UCB Pharma GmbH
2005250103	Benzoxazolone derivatives, processes for preparing them and their uses	UCB, S.A.
2005256468	Novel use of peptide compounds for treating essential tremor and other tremor syndromes	UCB Pharma GmbH
2005251884	Process for preparing 2-oxo-1-pyrrolidine derivatives by intramolecular allylation	UCB
<u>2005261953</u>	Pharmaceutical composition of piperazine derivatives	UCB Farchim SA
2005263526	Indolone derivatives, processes for preparing them and their uses	UCB, S.A.
2005276634	Use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain	UCB Pharma GmbH
2005291456	Improved synthesis scheme for lacosamide	UCB Pharma GmbH
2005281783	Sigma receptor ligands	UCB Pharma, S.A.
2006274263	Pharmaceutical compositions comprising levetiracetam and process for their preparation	UCB Pharma, S.A.
2005305677	Neutralising antibody molecules having specificity for human IL-17	UCB Pharma, S.A.
<u>2005305681</u>	Process for obtaining antibodies	UCB Pharma, S.A.
<u>2005308941</u>	Process for Pd-catalysed C-N coupling in specific solvent systems	UCB Pharma, S.A.
<u>2005305700</u>	Process for obtaining antibodies	UCB Pharma S.A.
2006208630	SPM 927 for add-on therapy of schizophrenia	UCB Pharma GmbH
2006222298	Pyroglutamate salts and their use in the optical resolution of intermediates for the synthesis of dextrocetirizine and levocetirizine	UCB Farchim SA
<u>2006228702</u>	Compounds comprising an oxazoline or thiazoline moiety, processes for making them, and their uses	UCB Pharma, S.A.
2006228690	Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses	UCB Pharma S.A.
2006242431	Sclerostin binding agents	UCB Pharma S.A. ; Amgen, Inc.
2006242476	Sclerostin epitopes	UCB Pharma S.A. ; Amgen, Inc.
2006248789	PSKI and its modulators for the treatment/diagnosis of cancer	UCB Pharma S.A.
2006239018	Fused thiazole derivatives as kinase inhibitors	UCB Pharma S.A.
2006254335	2-oxo-1-pyrrolidine derivatives and their therapeutic use on the central nervous system	UCB Pharma, S.A.
<u>2006254336</u>	2 -oxo-I -pyrrolidine derivatives/ processes for preparing them and their therapeutic use on the central nervous system	UCB Pharma S.A.

Number	Title	Owner
<u>2006256954</u>	Use op brivaracetam for the treatment of diseases characterized by progressive myoclonic epilepsy	UCB Pharma, S.A.
<u>2006254772</u>	2,6 quinolinyl derivatives, processes for preparing them and their use as medicament	UCB Pharma S.A.
2006264684	Process for attaching effector molecules to proteins	UCB Pharma S.A.
<u>2006271416</u>	Modified antibody fragments	UCB Pharma S.A
<u>2006290567</u>	Comb polymers	UCB Pharma S.A
2006291524	4-substituted pyrrolidin-2-ones and their use	UCB Pharma S.A
<u>2006298590</u>	Expression control using antibody expression optimisation sequences	UCB Pharma S.A.
<u>2006308167</u>	Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses	UCB Pharma, S.A.
2008202280	Formulations	UCB Farchim SA
<u>2006322297</u>	3-carboxy2-oxo-1 -pyrrolidine derivatives and their uses	UCB Pharma, S.A.
<u>2006322349</u>	Xanthine derivatives, processes for preparing them and their uses	UCB Pharma, S.A.
<u>2006323490</u>	Antibody molecules having specificity for human IL-6	UCB Pharma, S.A.
<u>2006318950</u>	Bioassays	UCB Pharma S.A.
2007211377	Thieno-pyridine derivatives as MEK inhibitors	UCB Pharma S.A.
<u>2008207533</u>	Methods for diagnosis and treatment of epithelial- derived cancers	UCB Pharma S.A.
<u>2007228939</u>	Process for preparing lhalo-2,7-naphthyridinyl derivatives	UCB Pharma S.A.
<u>2007260267</u>	New chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof	UCB Pharma GmbH
2007260208	Peptide compounds for treating refractory status epilepticus	UCB Pharma GmbH
<u>2007279092</u>	Substituted aniline derivatives	UCB Pharma S.A.
<u>2007311689</u>	Antibody molecules which bind IL-17A and IL-17F	UCB Pharma S.A.
<u>2009203044</u>	Formulations	UCB Farchim SA
<u>2008232409</u>	Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof	Biogen Idec MA Inc. ; UCB Pharma S.A.
2008240832	Histamine H3 receptor ligands comprising a cyclobutoxy group	UCB Pharma S.A.
2008269577	Fused thiazole derivatives as kinase inhibitors	UCB Pharma S.A.
<u>2008285765</u>	Sulfanyl derivatives and their use as synthesis intermediates	UCB Pharma S.A.
2008328920	Polymorphic form of Rotigotine	UCB Pharma GmbH
<u>2009207693</u>	Compounds comprising a cyclobutoxy group	UCB Pharma, S.A.
<u>2008347991</u>	Systems for administering medication for rheumatoid arthritis patients	UCB Pharma SA
<u>2009221177</u>	Pharmaceutical solutions, process of preparation and therapeutic uses	UCB Pharma, S.A.
2009253961	Compounds comprising a cyclobutoxy group	UCB Pharma, S.A.
<u>2009313037</u>	Novel process for the preparation of amino acid derivatives	UCB Pharma GmbH

Number	Title	Owner
<u>2009317279</u>	Prolonged release formulations comprising an 2- oxo-1-pyrrolidine derivate	UCB Pharma, S.A.
<u>2009317280</u>	Prolonged release formulations comprising an 2 - oxo1 -pyrrolidine derivative	UCB Pharma, S.A.
<u>2010215646</u>	Pharmaceutical compositions comprising 2-oxo-1- pyrrolidine derivatives	UCB Pharma, S.A.
<u>2010209790</u>	Pharmaceutical compositions comprising 2-oxo-1- pyrrolidine derivatives	UCB Pharma, S.A.
2010216152	Antibody molecules having specificity for human OX40	UCB Pharma S.A.
<u>2010222693</u>	Antibody molecules having binding specificity for human IL-13	UCB Pharma S.A.
<u>2010265087</u>	Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis	UCB Pharma GmbH
2012200748	Compositions and methods for increasing bone mineralization	UCB Manufacturing, Inc.
2010294905	Treatment of autoimmune and inflammatory diseases with epratuzumab	UCB Pharma, S.A.
2010299640	Bacterial host strain	UCB Pharma S.A.
2010334805	Polyvinylpyrrolidone for the stabilization of a solid dispersion of the noncrystalline form of rotigotine	LTS LOHMANN THERAPIE-SYSTEME AG ; UCB Pharma GmbH
2010310100	2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives	UCB Pharma, S.A.
<u>2011206586</u>	Bacterial host strain comprising a mutant spr gene and a wild-type Tsp gene	UCB Pharma S.A.
<u>2011206587</u>	Bacterial host strain expressing recombinant DsbC and having reduced Tsp activity	UCB Pharma S.A.
<u>2011206584</u>	Bacterial host strain comprising a mutant spr gene and having reduced Tsp activity	UCB Pharma S.A.
<u>2012216589</u>	Sclerostin epitopes	UCB Pharma S.A.; Amgen Inc.
<u>2011212493</u>	Process for obtaining antibodies	UCB Pharma, S.A.
<u>2012238247</u>	Sclerostin binding agents	Amgen, Inc.; UCB Pharma S.A.

Terms and Conditions

General

The information provided in this report is not in the nature of legal or other professional advice.

The information provided in this report is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals regarding any information in this report.

Patents, patent applications, trademarks and trademark applications shown as lapsed or ceased may be restored at a later date.

Disclaimer of warranty and limitation of liability

Neither IPMonitor, its affiliates nor any of their respective employees, agents, third party content providers or licensors warrant that the information contained in this report is error free; nor do they make any warranty as to the accuracy, reliability or content of any information in this report.

This report is provided on an "as is" basis; to the maximum extent permitted by law, IPMonitor disclaims all representations and warranties, express or implied, with respect to any information conatined in this report. In addition, IPMonitor does not represent or warrant that the information contained in this report is accurate, complete or current.

This disclaimer of liability applies to any damages or injury caused by any failure of performance, error, omission, interruption, deletion, defect, delay in operation or transmission, computer virus, communication line failure, theft or destruction or unauthorized access to, alteration of, or use of record, whether for breach of contract, tortious behavior, negligence, or under any other cause of action.

Copyright

The content of this report may be protected by copyright laws and treaties around the world and all rights relating to the same are reserved. Any paper or digital copies of this report are not to be modified or any illustrations or any graphics used separately from any accompanying text.

Arbitration

Any dispute or difference whatsoever arising out of or in connection with this report shall be submitted to arbitration in accordance with, and subject to, The Institute of Arbitrators & Mediators Australia Rules for the Conduct of Commercial Arbitrations.

IPMonitor reserves the right to update the Terms and Conditions at any time without notice. Please see the full Terms and Conditions at www.IPMonitor.com.au/trademarks/info/terms